|
|
 |
|
Viewing report
|
|
|
|
Specialty Pharma: Guide to Success at the New Frontier
Decision Resources, Inc, May 2007, Pages: 27
Recently catapulted into the pharmaceutical industry limelight, Specialty Pharma may well be the solution to many of Big Pharma’s current woes. Its success driven largely by astute manipulation of the business and market issues that currently plague Big Pharma, Specialty Pharma has shown the potential to capture and firmly command market spaces once dominated by Big Pharma.
Get the Answers You Need to Shape Your Strategy
- The emergence of Specialty Pharma as a market force occurred as Big Pharma and Mid Pharma began to consolidate. What strategies will Specialty Pharma pursue as it continues to capitalize on Big Pharma’s looming market problems?
- Patents have become a trapdoor for both Big Pharma and Mid Pharma alike; once patents expire, these companies find themselves hanging in a market abyss. What methods are Specialty Pharma using to sidestep such patent expiry pitfalls? What specific markets or patient cohorts are receiving attention from Specialty Pharma?
- Value-for-money is the mantra of today’s knowledgeable and organized health care customers—a challenge for Specialty Pharma, which has received condemnation over its pricing of orphan drugs. How can Specialty Pharma best present its pricing practices to an increasingly informed and sceptical consumer audience?
Scope
- Market drivers: business factors and issues that are driving the transformation of the pharma market.
- Market overview: market conditions that contributed to the emergence and subsequent growth of Specialty Pharma.
- Success and uncertainty: how Specialty Pharma’s success has altered its market space, and how these companies need to respond to the changing marketplace.
- Specialty Pharma business models: 11 business models, with examples of companies that utilize them.
- Challenges: threats to the continued growth of the Specialty Pharma sector.
- Market outlook: opportunities and strategies for Specialty Pharma companies to succeed in today’s changing pharma business environment.
|
|
|
|
